Product Images Memantine Hydrochloride

This is a graph showing the time course of change in ADCS-ADL score for patients completing 28 weeks of treatment with either Placebo or Memantine Hydrochloride. The graph indicates clinical improvement with Memantine Hydrochloride compared to Placebo.*

The provided text is a figure caption showing a graph of the percentage of patients completing 28 weeks of double-blind treatment with specified changes from baseline in ADCS-ADL scores. The plot compares the effectiveness of two drugs, Placebo and Memantine Hydrochloride, in treating Alzheimer's disease. The graph shows the percentage of patients at different levels of improvement in their ADCS-ADL scores from baseline. There is no additional information available in the provided text.*

The text describes a graph labeled as "Figure 3" that shows the time course of change from baseline in SIB (Severe Impairment Battery) score for patients who completed 28 weeks of treatment. The graph includes two lines representing the mean change from baseline for a placebo group and a group treated with memantine hydrochloride. There are also labels for clinical improvement and clinical decline.*

The text describes a figure labeled as "Figure 4", which shows the cumulative percentage of patients completing 28 weeks of double-blind treatment with specified changes from baseline in SIB scores. The figure also includes two drugs, "Placebo" and "Memantine Hydrochloride".*

The text describes a figure showing the time course of change from baseline in ADCS-ADL score for patients completing 24 weeks of treatment with either placebo/donepezil or memantine hydrochloride/donepezil. It indicates that there was clinical improvement in the ADCS-ADL score over 24 weeks of treatment with memantine hydrochloride/donepezil. However, there is no information available about the baseline or the conditions being treated.*

The text appears to be the results of a clinical trial for treatments of Alzheimer's disease. Two treatments are mentioned, Placebo/Donepezil and Memantine Hydrochloride/Donepezil. The graph shows the percentage of patients completing 24 weeks of treatment and their corresponding changes from baseline in ADCS-ADL scores. Unfortunately, without more context, it's difficult to draw any meaningful conclusion about the effectiveness of the treatments.*

This is a figure showing the time course of change from baseline in SIB score for patients who completed 24 weeks of treatment with either placebo/donepezil or memantine hydrochloride/donepezil. The figure is divided into weeks of treatment on the x-axis and mean change from baseline on the y-axis. No further information is available in the text.*

This is a graph showing the Cumulative Percentage of Patients completing a 24-week double-blind treatment with specified changes from baseline in SIBscores. There are two different treatments shown; Placebo/Donepezil and Memantine Hydrochloride/Donepezil. The x-axis shows the change in SIBscores from baseline, ranging from -30 to +20, and the y-axis shows the cumulative percentage of patients who achieved that change.*

This is a prescription medicine with the name Memantine Hydrochloride Tablets, identified by NOC 47335-321.86, which comes in the form of a bottle containing 60 tablets distributed by SUN. Other than that, the text is not available for evaluation.*